Rapport Therapeutics, Inc. (NASDAQ:RAPP - Get Free Report) was down 6.3% during trading on Friday . The company traded as low as $14.47 and last traded at $14.41. Approximately 35,897 shares were traded during mid-day trading, a decline of 78% from the average daily volume of 165,247 shares. The stock had previously closed at $15.38.
Wall Street Analyst Weigh In
A number of brokerages have issued reports on RAPP. Citizens Jmp assumed coverage on shares of Rapport Therapeutics in a research report on Tuesday, April 8th. They set a "mkt outperform" rating on the stock. JMP Securities reiterated a "market outperform" rating and set a $28.00 price objective on shares of Rapport Therapeutics in a research report on Tuesday.
Read Our Latest Stock Analysis on Rapport Therapeutics
Rapport Therapeutics Price Performance
The stock has a fifty day moving average of $11.19 and a 200 day moving average of $12.15. The firm has a market capitalization of $528.37 million and a P/E ratio of -4.20.
Rapport Therapeutics (NASDAQ:RAPP - Get Free Report) last posted its earnings results on Thursday, May 8th. The company reported ($0.68) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.77) by $0.09. Equities analysts forecast that Rapport Therapeutics, Inc. will post -3.65 EPS for the current fiscal year.
Institutional Inflows and Outflows
Large investors have recently bought and sold shares of the business. KLP Kapitalforvaltning AS bought a new position in Rapport Therapeutics during the 4th quarter valued at about $34,000. Deutsche Bank AG purchased a new position in Rapport Therapeutics during the fourth quarter valued at approximately $41,000. Virtus ETF Advisers LLC bought a new position in Rapport Therapeutics in the 4th quarter worth $66,000. Corebridge Financial Inc. grew its position in shares of Rapport Therapeutics by 79.1% during the first quarter. Corebridge Financial Inc. now owns 8,271 shares of the company's stock worth $83,000 after purchasing an additional 3,653 shares in the last quarter. Finally, Wells Fargo & Company MN raised its position in shares of Rapport Therapeutics by 38.9% during the fourth quarter. Wells Fargo & Company MN now owns 4,824 shares of the company's stock valued at $86,000 after buying an additional 1,352 shares during the last quarter.
About Rapport Therapeutics
(
Get Free Report)
Rapport Therapeutics Inc is a clinical-stage biotechnology company. It focused on discovery and development of transformational small molecule medicines for patients suffering from central nervous system disorders. Rapport Therapeutics Inc is based in BOSTON.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Rapport Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Rapport Therapeutics wasn't on the list.
While Rapport Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
